Results 71 to 80 of about 273,871 (338)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Widespread rash in lung adenocarcinoma

ESMO Open, 2018
A 68-year-old man is being treated with cisplatin-pemetrexed in the first line for bone metastatic lung adenocarcinoma. There is partial response and very good tolerance with no grade 3–4 toxicities. After six cycles of doublet therapy, the patient follows on pemetrexed maintenance. Six months later, he develops a hot and itchy rash with …
José Miguel Jurado, Fernando Gálvez-Montosa, Francisco Almazan   +2 more
openaire   +2 more sources

TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma

Cancer Cell International, 2020
Background Lung adenocarcinoma has surpassed lung squamous cell carcinoma as the most common type of non-small cell lung cancer. In this study, we had tested the biological role of TRIM2 in lung adenocarcinoma. Methods TRIM2 abundance in clinical tissues
Zhaoxian Lin, Xing Lin, Lihuan Zhu, Jianyuan Huang, Yangyun Huang   +4 more
doaj   +1 more source

Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks [PDF]

arXiv, 2019
Classification of histologic patterns in lung adenocarcinoma is critical for determining tumor grade and treatment for patients. However, this task is often challenging due to the heterogeneous nature of lung adenocarcinoma and the subjective criteria for evaluation.
arxiv  

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Molecular biomarkers for lung adenocarcinoma [PDF]

European Respiratory Journal, 2017
The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors has led to growing interest in identifying additional targetable oncogenes in nonsmall cell lung cancer. Although the therapeutic impact of the discovery of these alterations has now been widely demonstrated, the epidemiological data associated with each of
Anne Pradines, Julien Mazieres, Olivier Calvayrac, Elvire Pons, Nicolas Guibert, Nicolas Guibert   +5 more
openaire   +3 more sources

Expression and clinical role of in lung adenocarcinoma

Journal of International Medical Research
Objective To explore the levels of expression and clinical role of peroxiredoxin 6 ( PRDX6 ) in lung adenocarcinoma. Methods This retrospective study used a series of bioinformatics methods to detect the levels of expression of and mutations in the PRDX6
Zixin Chen, Junjun Lin, Huifang Wang, Jing Wang, Zhou Zhang   +4 more
doaj   +1 more source

Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1

Molecular Oncology, 2021
Recent studies revealed the role of dynamin‐related protein 1 (DRP1), encoded by the DNM1L gene, in regulating the growth of cancer cells of various origins. However, the regulation, function, and clinical significance of DRP1 remain undetermined in lung
Kuei‐Pin Chung, Yen‐Lin Huang, Yi‐Jung Chen, Yi‐Hsiu Juan, Chia‐Lang Hsu, Kiichi Nakahira, Yen‐Tsung Huang, Mong‐Wei Lin, Shang‐Gin Wu, Jin‐Yuan Shih, Yih‐Leong Chang, Chong‐Jen Yu   +11 more
doaj   +1 more source

Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development [PDF]

arXiv, 2023
Mutated genes may lead to cancer development in numerous tissues. While more than 600 cancer-causing genes are known today, some of the most widespread mutations are connected to the RAS gene: RAS mutations are found in approximately 25% of all human tumors.
arxiv  

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source